CM
UTHR icon

Castleark Management’s United Therapeutics UTHR Stock Holding History

Castleark Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,850
Closed -$514K – 324
2022
Q4 		$514K Buy
+1,850
New +$467K 0.03% 229
2022
Q3 		– Sell
-25,350
Closed -$5.97M – 341
2022
Q2 		$5.97M Buy
+25,350
New +$5.15M 0.32% 68
2015
Q3 		– Sell
-54,140
Closed -$9.42M – 404
2015
Q2 		$9.42M Buy
54,140
+25,550
+89% +$4.6M 0.25% 120
2015
Q1 		$4.93M Buy
+28,590
New +$4.36M 0.12% 193

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Castleark Management's UTHR Position: Q1 2023 in Review

Castleark Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 1,850 shares — an estimated $514K sold.

Castleark Management first reported a position in UTHR in Q1 2015 and held it in 4 quarters. The position peaked at $9.42M in Q2 2015. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Castleark Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Castleark Management sold 1,850 United Therapeutics shares in Q1 2023, an estimated $514K.
  • Castleark Management first reported a position in United Therapeutics in Q1 2015 and held it in 4 quarters.
  • Castleark Management's United Therapeutics position peaked at $9.42M in Q2 2015.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Castleark Management's 13F filing for Q1 2023, filed 16 May 2023.